Release Date: 2024-06-10
68Ga PSMA PET/CT in Patients with Prostate Cancer
Sadiye Altun Tuzcu (Author)
Release Date: 2024-06-10
Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is a new method of imaging prostate cancer that increases diagnostic accuracy in detecting reccurrent disease or metastasis and guiding therapy. Gallium-68 PSMA ligand PET/CT has increased sensitivity of detection of local recurrence or metastases at low PSA levels. PSMA PET/CT has also inceased sensitivity and [...]
Media Type
Buy from
Price may vary by retailers
| Work Type | Book Chapter |
|---|---|
| Published in | The Radiology of Cancer |
| First Page | 498 |
| Last Page | 504 |
| DOI | https://doi.org/10.69860/nobel.9786053359364.31 |
| Page Count | 7 |
| Copyright Holder | Nobel Tıp Kitabevleri |
| License | https://nobelpub.com/publish-with-us/copyright-and-licensing |
Sadiye Altun Tuzcu (Author)
Associate Professor, Dicle University
https://orcid.org/0000-0003-3326-5358
3Associate Professor Şadiye Altun Tuzcu graduated from Dicle University Faculty of Medicine in 1996. She received her specialty training at Dicle University Faculty of Medicine, Department of Nuclear Medicine, between 2001 and 2005. After working in public hospitals and various private institutions, she worked as an academician at Dicle University, Department of Nuclear Medicine in 2019. She has many national and international research articles, posters and oral presentations, book chapters in her field.
Louveau, A., et al. (2015). “Structural and functional features of central nervous system lymphatic vessels.” Nature 523(7560): 337-341.
Cloughesy, Timothy F., et al. “Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.” Nature medicine 25.3 (2019): 477-486.
Reardon, D. A., et al. “OS10. 3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143.” Neuro-oncology 19.suppl_3 (2017): iii21-iii21.
Nayak, Lakshmi, et al. “Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma.” Clinical Cancer Research 27.4 (2021): 1048-1057.
Omuro, Antonio, et al. “Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.” Neuro-oncology 25.1 (2023): 123-134.
Pinheiro, Samuel Luca Rocha, et al. “Immunotherapy in glioblastoma treatment: Current state and future prospects.” World Journal of Clinical Oncology 14.4 (2023): 138.
Sampson, John H., et al. “Brain immunology and immunotherapy in brain tumours.” Nature Reviews Cancer 20.1 (2020): 12-25.
Patel, J. J., Levy, D. A., Nguyen, S. A., Knochelmann, H. M., & Day, T. A. (2020). Impact of PD‐L1 expression and human papillomavirus status in anti‐PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma—systematic review and meta‐analysis. Head & neck, 42(4), 774-786.
Fayette, J., Licitra, L. F. L., Harrington, K. J., Haddad, R., Siu, L. L., Liu, Y. C.,... & Cohen, R. B. (2023). 854O INTERLINK-1: Phase III study of cetuximab (CTX)±monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI). Annals of Oncology, 34, S554-S555.
Haddad, R. I., Harrington, K., Tahara, M., Ferris, R. L., Gillison, M., Fayette, J.,... & Argiris, A. (2023). Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651. Journal of Clinical Oncology, 41(12), 2166-2180.
Dzienis, M. R., Cundom, J. E., Fuentes, C. S., Hansen, A. R., Nordlinger, M. J., Pastor, A. V.,... & De Castro, G. (2022). 651O Pembrolizumab (pembro)+ carboplatin (carbo)+ paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study. Annals of Oncology, 33, S839-S840
Sacco, A. G., Chen, R., Worden, F. P., Wong, D. J., Adkins, D., Swiecicki, P.,... & Cohen, E. E. (2021). Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. The Lancet Oncology, 22(6), 883-892.
Machiels, J. P., Tao, Y., Licitra, L., Burtness, B., Tahara, M., Rischin, D.,... & Powell, M. (2024). Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. The Lancet Oncology.
Ferris, R. L., Spanos, W. C., Leidner, R., Gonçalves, A., Martens, U. M., Kyi, C.,... & Topalian, S. L. (2021). Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. Journal for immunotherapy of cancer, 9(6).
Uppaluri, R., Campbell, K. M., Egloff, A. M., Zolkind, P., Skidmore, Z. L., Nussenbaum, B.,... & Adkins, D. R. (2020). Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus–unrelated head and neck cancer: a multicenter, phase II trial. Clinical Cancer Research, 26(19), 5140-5152.
Klochikhin, A., Haddad, R. I., Meirovitz, A., Safina, S., Brana, I., Le Tourneau, C.,... & Adkins, D. (2023). KEYNOTE-689: a phase 3 study of neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable, locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). European Journal of Surgical Oncology, 49(1), e9
Vos, J. L., Elbers, J. B., Krijgsman, O., Traets, J. J., Qiao, X., van der Leun, A. M.,... & Zuur, C. L. (2021). Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nature communications, 12(1), 7348.
Yungan, T. A. O., Sun, X. S., Pointreau, Y., Le Tourneau, C., Sire, C., Kaminsky, M. C., & Bourhis, J. (2023). Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. European journal of cancer, 183, 24-37.
Psyrri, A., Fayette, J., Harrington, K., Gillison, M., Ahn, M. J., Takahashi, S.,... & KESTREL Investigators. (2023). Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Annals of Oncology, 34(3), 262-274.
Colevas, A. D., Bahleda, R., Braiteh, F., Balmanoukian, A., Brana, I., Chau, N. G.,... & Powderly, J. (2018). Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Annals of Oncology, 29(11), 2247-2253.
Ferris, R. L., Haddad, R., Even, C., Tahara, M., Dvorkin, M., Ciuleanu, T. E.,... & Licitra, L. (2020). Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Annals of Oncology, 31(7), 942-950.
| onix_3.0::thoth | Thoth ONIX 3.0 |
|---|---|
| onix_3.0::project_muse | Project MUSE ONIX 3.0 |
| onix_3.0::oapen | OAPEN ONIX 3.0 |
| onix_3.0::jstor | JSTOR ONIX 3.0 |
| onix_3.0::google_books | Google Books ONIX 3.0 |
| onix_3.0::overdrive | OverDrive ONIX 3.0 |
| onix_2.1::ebsco_host | EBSCO Host ONIX 2.1 |
| csv::thoth | Thoth CSV |
| json::thoth | Thoth JSON |
| kbart::oclc | OCLC KBART |
| bibtex::thoth | Thoth BibTeX |
| doideposit::crossref | CrossRef DOI deposit |
| onix_2.1::proquest_ebrary | ProQuest Ebrary ONIX 2.1 |
| marc21record::thoth | Thoth MARC 21 Record |
| marc21markup::thoth | Thoth MARC 21 Markup |
| marc21xml::thoth | Thoth MARC 21 XML |
